Human Anti-IL17RA scFv-Fc Chimera (VS-0425-FY41) (CAT#: VS-0425-FY41)
The anti-IL17RA scFv-Fc is a novel therapeutic antibody designed to target the interleukin-17 receptor A (IL17RA), a key mediator in inflammatory responses. By binding specifically to IL17RA, this recombinant single-chain variable fragment fused with an IgG Fc domain helps to inhibit IL-17 signaling, which is implicated in various autoimmune conditions. The product is engineered for enhanced stability and longer half-life in circulation, making it a promising candidate for chronic disease treatment. Preclinical studies have demonstrated its potential to reduce inflammation and tissue damage in models of diseases such as psoriasis and rheumatoid arthritis. Additionally, its dual mechanism of action not only blocks IL-17 signaling but also modulates immune responses. The anti-IL17RA scFv-Fc represents a significant advancement in targeted therapies for inflammatory diseases.
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.

(Immunofluorescent staining of human cell line U-251 MG shows localization to nucleoplasm & cytosol.)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/24996/if_selected.jpg

(Glandular cells Staining: Medium Intensity: Moderate Quantity:>75% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/24996/59803_A_7_3.jpg

(Hepatocytes Staining: Low Intensity: Moderate Quantity: <25% Location: Cytoplasmic/ membranous)
* Image credit: Human Protein Atlas v21.proteinatlas.org/images/24996/59803_A_7_4.jpg

(Cell lines ordered by descending RNA expression order)
* Image credit: Human Protein Atlas v21.proteinatlas.org/ENSG00000177663-IL17RA
Specifications
- Host Species
- Human
- Type
- Human IgG2, scFv-Fc
- Specificity
- Human IL17RA
- Species Reactivity
- Human
- Applications
- Western Blot, ELISA, Dot Blot
- Related Disease
- Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis
Product Property
- Purity
- >95% as determined by SDS-PAGE
- Concentration
- Please refer to the vial label for the specific concentration.
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
- Shipping
- Ice packs
Applications
- Application Notes
- Western Blot: 2 μg/mL
Dot Blot: 2 μg/mL
The optimal dilution concentration is determined by the experiment.
Target
- Alternative Names
- Interleukin 17 Receptor A
- Gene ID
- 23765
- UniProt ID
- Q96F46
- Long Name
- Interleukin 17 Receptor A
- Cellular Localization
- Cell membrane, Secreted
- Post Translation Modifications
- Glycosylated.
Glycosylation at Asn49, Asn54, Asn67, Asn206, Asn225, Asn242, and Asn265
Modification sites at PhosphoSitePlus
Glycosylation from GlyGen 8 sites, 10 N-linked glycans (4 sites), 1 O-linked glycan (1 site)
- Protein Refseq
- NP_001276834.1; NP_055154.3
- Function
- Receptor for IL17A and IL17F, major effector cytokines of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity.
Receptor for IL17A.
Receptor for IL17F.
Binds to IL17A with higher affinity than to IL17F.
Binds IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RC.
Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC.
Cytokine binding triggers homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter, leading to TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways, ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation.
Involved in antimicrobial host defense primarily promoting neutrophil activation and recruitment at infection sites to destroy extracellular bacteria and fungi.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "IL17RA"
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NABL-093 | Recombinant Anti-human IL17RA VHH Single Domain Antibody | WB, ELISA, IHC, FC, FuncS | Llama VHH |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for VS-0425-FY41. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: ELISA, FC, IP, FuncS, IF, Neut, ICC
Application: Depletion, FuncS
Application: WB, ELISA, FC, IHC, IP
Application: ELISA, FC
Application: IF, IP, Neut, FuncS, ELISA, FC
Application: ELISA, Block, WB, FC, IP
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.